Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MMP14 | P50281 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11676287 | 0.80 | — | — | |
| SCHEMBL7268348 | 0.80 | — | — | |
| SCHEMBL10597507 | 0.78 | CYP3A4 (0.48) | CYP3A4ALDH1A1L3MBTL1TSHRATM | |
| SCHEMBL897065 | 0.76 | CYP3A4 (0.39) | CYP3A4ALDH1A1L3MBTL1TSHR | |
| SCHEMBL18888023 | 0.76 | CYP3A4 (0.47) | CYP3A4ALDH1A1L3MBTL1TSHRATM | |
| SCHEMBL3381762 | 0.75 | — | — | |
| SCHEMBL11852563 | 0.74 | CYP3A4 (0.41) | CYP3A4ALDH1A1L3MBTL1TSHRATM | |
| SCHEMBL80432 | 0.74 | CYP3A4 (0.67) | CYP3A4ALDH1A1L3MBTL1TSHRATM | |
| SCHEMBL8401011 | 0.73 | CYP3A4 (0.65) | CYP3A4ALDH1A1L3MBTL1TSHRATM | |
| SCHEMBL10379838 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9248117-B2 | Substituted N,N-dihaloamines as antimicrobials | NOVABAY PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2629607-A2 | ANTIMICROBIAL POLYETHER AND POLYOL COMPOUNDS | NovaBay Pharmaceuticals, Inc. (US) | 2013-08-28 | — | — | EP | disclosed |
| CN-103260402-A | Antimicrobial polyether and polyol compounds | NOVABAY PHARMACEUTICALS INC | 2013-08-21 | — | — | CN | disclosed |
| US-20120129793-A1 | Antimicrobial Polyether and Polyol Compounds | NOVABAY PHARMACEUTICALS, INC. | 2012-05-24 | — | — | US | disclosed |
| WO-2012054521-A2 | ANTIMICROBIAL POLYETHER AND POLYOL COMPOUNDS | NOVABAY PHARMACEUTICLAS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129793-A1 | Antimicrobial Polyether and Polyol Compounds | POLR1C, DPM1, PRF1 | CYP3A4 1242/4885ALDH1A1 1198/4885L3MBTL1 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.